A phase 1 trial of direct intraputamenal injections of CDNF showed good tolerability, though a 12-month treatment of moderate to severe PD sufferers did not meet the secondary endpoint of improved PD motor scores [106]. This evidence concerns the gene CDNF and Parkinson disease.